Skip to main content
Log in

Effect of intravenous hydralazine infusion on maternal plasma nitric oxide levels in gestations complicated with severe preeclampsia: a pilot study

Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Aim

To investigate the effect of intravenous hydralazine infusion on maternal nitric oxide (NO) levels.

Methods

This pilot study comprised 40 (n = 40) gestations complicated with severe preeclampsia to whom maternal plasma NO levels were determined by chemiluminescence before and after hydralazine administration. Blood pressure values were concomitantly assessed.

Results

After 20 min of intravenous hydralazine infusion blood pressure values decrease significantly in term and preterm gestations. This was accompanied by an overall significant decrease in mean plasma NO values (38.7 ± 12.9 to 35.4 ± 13.9 μmol/L, p < 0.05). Despite this, NO values decreased in 67.5% of cases (a 17.6% from baseline) and increased in 32.5% (a 14.8% from baseline) (p < 0.05 for both). Blood pressure decrease (%) was lower (systolic and diastolic) among those displaying a NO decrement than in the increment group. Interestingly, gestational age was higher in the group displaying decreased NO; however, this did not reach statistical significance (37.5 ± 2.7 vs. 35.9 ± 2.8 weeks, p = 0.08).

Conclusion

The results of this study fail to demonstrate a similar NO secretion after hydralazine infusion in women with severe preeclampsia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pérez-López FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS (2010) Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci 17:511–531

    Article  PubMed  Google Scholar 

  2. Pridjian G, Puschett JB (2002) Preeclampsia. Part 2: experimental and genetic considerations. Obstet Gynecol Surv 57:619–640

    Article  PubMed  Google Scholar 

  3. Friedman SA, Taylor RN, Roberts JM (1991) Pathophysiology of preeclampsia. Clin Perinatol 4:661–682

    Google Scholar 

  4. Powers RW, Catov JM, Bodnar LM, Gallaher MJ, Lain KY, Roberts JM (2008) Evidence of endothelial dysfunction in preeclampsia and risk of adverse pregnancy outcome. Reprod Sci 15:374–381

    Article  PubMed  CAS  Google Scholar 

  5. Seligman SP, Buyon JP, Clancy RM, Young BK, Abramson SB (1994) The role of NO in the pathogenesis of preeclampsia. Am J Obstet Gynecol 171:944–948

    PubMed  CAS  Google Scholar 

  6. Conrad K, Kerchner L, Mosher M (1999) Plasma and 24-h NOx and cGMP during normal pregnancy and preeclampsia in women on a reduced NOx diet. Am J Physiol 277:F48–F57

    PubMed  CAS  Google Scholar 

  7. Begum S, Yamasaki M, Mochizuki M (1996) Urinary levels of nitric oxide metabolites in normal pregnancy and preeclampsia. J Obstet Gynaecol Res 22:551–559

    PubMed  CAS  Google Scholar 

  8. Steinert JR, Wyatt AW, Poston L, Jacob R, Mann GE (2002) Preeclampsia is associated with altered Ca2+ regulation and NO production in human fetal venous endothelial cells. FASEB J 16:721–723

    PubMed  CAS  Google Scholar 

  9. Chen LK, Huang CH, Yeh HM et al (2007) Polymorphisms in the endothelial nitric oxide synthase gene may be protective against preeclampsia in a Chinese population. Reprod Sci 14:175–181

    Article  PubMed  Google Scholar 

  10. Bernardi F, Constantino L, Machado R, Petronilho F, Dal-Pizzol F (2008) Plasma nitric oxide, endothelin-1, arginase and superoxide dismutase in pre-eclamptic women. J Obstet Gynaecol Res 34:957–963

    PubMed  CAS  Google Scholar 

  11. Matsubara K, Matsubara Y, Hyodo S, Katayama T, Ito M (2010) Role of nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia. J Obstet Gynaecol Res 36:239–247

    Article  PubMed  CAS  Google Scholar 

  12. Teran E, Escudero C, Moya W (2006) Abnormal release of nitric oxide from nitrosoproteins during preeclampsia. Int J Gynecol Obstet 92:260–261

    Article  CAS  Google Scholar 

  13. Teran E, Escudero C, Vivero S, Enriquez A, Calle A (2004) Intraplatelet cyclic guanosine-3′,5′-monophosphate levels during pregnancy and preeclampsia. Hypertens Pregnancy 23:303–308

    Article  PubMed  CAS  Google Scholar 

  14. Diejomaoh FM, Omu AE, Al-Busiri et al (2004) Nitric oxide production is not altered in preeclampsia. Arch Gynecol Obstet 269:237–243

    Article  PubMed  CAS  Google Scholar 

  15. Giles TD (2006) Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease. J Clin Hypertens (Greenwich) 8(12 Suppl 4):2–16

    CAS  Google Scholar 

  16. Tacchi D (1961) Peripheral vascular response to hydralazine in toxemia of pregnancy. Obstet Gynecol 18:300–304

    PubMed  CAS  Google Scholar 

  17. Vigil-De Gracia P, Lasso M, Ruiz E, Vega-Malek JC, de Mena FT, López JC; or the HYLA treatment study (2006) Severe hypertension in pregnancy: hydralazine or labetalol. A randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 128:157–162

  18. Sekiya M, Sato M, Funada J, Ohtani T, Akutsu H, Watanabe K (2005) Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 46:63–67

    Article  PubMed  CAS  Google Scholar 

  19. Magee LA, von Dadelszen P (2009) The management of severe hypertension. Semin Perinatol 33:138–142

    Article  PubMed  Google Scholar 

  20. Bauer JA, Fung HL (1991) Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Circulation 84:35–39

    PubMed  CAS  Google Scholar 

  21. Unger P, Berkenboom G, Fontaine J (1993) Interaction between hydralazine and nitrovasodilators in vascular smooth muscle. J Cardiovasc Pharmacol 21:478–483

    Article  PubMed  CAS  Google Scholar 

  22. Münzel T, Kurz S, Rajagopalan S et al (1996) Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 98:1465–1470

    Article  PubMed  Google Scholar 

  23. Thomas GR, DiFabio JM, Gori T, Parker JD (2007) Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism. J Am Coll Cardiol 49:1289–1295

    Article  PubMed  CAS  Google Scholar 

  24. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P (2003) Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 327:955–965

    Article  PubMed  CAS  Google Scholar 

  25. Ellershaw DC, Gurney AM (2001) Mechanisms of hydralazine induced vasodilation in rabbit aorta and pulmonary artery. Br J Pharmacol 134:621–631

    Article  PubMed  CAS  Google Scholar 

  26. Duley L, Meher S, Abalos E (2006) Management of pre-eclampsia. BMJ 332:463–468

    Article  PubMed  Google Scholar 

  27. Begum MR, Quadir E, Begum A, Akhter S, Rahman K (2002) Management of hypertensive emergencies of pregnancy by hydralazine bolus injection vs continuous drip: a comparative study. Medscape Women’s Health 7:1

    Google Scholar 

  28. Lopez-Jaramillo P, Narvaez M, Calle A et al (1996) Cyclic guanosine 3′,5′ monophosphate concentrations in pre-eclampsia: effects of hydralazine. Br J Obstet Gynaecol 103:33–38

    Article  PubMed  CAS  Google Scholar 

  29. Echols M, Yancy C (2006) Isosorbide dinitrate hydralazine combination therapy in African American with heart failure. Vasc Health Risk Manag 2:423–431

    Article  PubMed  CAS  Google Scholar 

  30. Terán E, Racines-Orbe M, Vivero S, Escudero C, Molina G, Calle A (2003) Preeclampsia is associated with a decrease in plasma coenzyme Q10 levels. Free Radic Biol Med 35:1453–1456

    Article  PubMed  Google Scholar 

  31. Mata-Greenwood E, Chen DB (2008) Racial differences in nitric oxide-dependent vasorelaxation. Reprod Sci 15:9–25

    Article  PubMed  CAS  Google Scholar 

  32. Savvidou MD, Vallance PJT, Nicolaides KH, Hingorani AD (2001) Endothelial nitric oxide synthase gene polymorphism and maternal vascular adaptation to pregnancy. Hypertension 38:1289–1293

    Article  PubMed  CAS  Google Scholar 

  33. Häkli T, Romppanen EL, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S (2003) Endothelial nitric oxide synthase polymorphism in preeclampsia. J Soc Gynecol Investig 10:154–157

    Article  PubMed  Google Scholar 

  34. Serrano NC, Casas JP, Díaz LA et al (2004) Endothelial NO synthase genotype and risk of preeclampsia: a multicenter case–control study. Hypertension 44:702–707

    Article  PubMed  CAS  Google Scholar 

  35. Sandrim VC, Palei AC, Cavalli RC et al (2008) eNOS haplotypes associated with gestational hypertension or preeclampsia. Pharmacogenomics 9:1467–1473

    Article  PubMed  CAS  Google Scholar 

  36. Heiskanen J, Romppanen EL, Hiltunen M et al (2002) Polymorphism in the tumor necrosis factor-alpha gene in women with preeclampsia. J Assist Reprod Genet 19:220–223

    Article  PubMed  Google Scholar 

  37. Häkli T, Romppanen EL, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S (2003) Plasminogen activator inhibitor-1 polymorphism in women with pre-eclampsia. Genet Test 7:265–268

    Article  PubMed  Google Scholar 

  38. Xu B, Thornton C, Tooher J et al (2009) Effects of anti-hypertensive drugs on production of soluble fms-like tyrosine kinase 1 and soluble endoglin from human normal and pre-eclamptic placentas in vitro. Clin Exp Pharmacol Physiol 36:839–842

    Article  PubMed  CAS  Google Scholar 

  39. Harskamp RE, Zeeman GG (2007) Preeclampsia: at risk for remote cardiovascular disease. Am J Med Sci 334:291–295

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Enrique Teran.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Teran, E., Briones, F., Nicolalde, V. et al. Effect of intravenous hydralazine infusion on maternal plasma nitric oxide levels in gestations complicated with severe preeclampsia: a pilot study. Arch Gynecol Obstet 285, 1183–1187 (2012). https://doi.org/10.1007/s00404-012-2217-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-012-2217-6

Keywords

Navigation